

ERRATUM

Open Access



# Erratum to: Results of multicenter double-blind placebo-controlled phase II clinical trial of Panagen preparation to evaluate its leukostimulatory activity and formation of the adaptive immune response in patients with stage II-IV breast cancer

Anastasia S. Proskurina<sup>1†</sup>, Tatiana S. Gvozdeva<sup>2†</sup>, Ekaterina A. Alyamkina<sup>1</sup>, Evgenia V. Dolgova<sup>1</sup>, Konstantin E. Orishchenko<sup>1</sup>, Valeriy P. Nikolin<sup>1</sup>, Nelly A. Popova<sup>1,3</sup>, Sergey V. Sidorov<sup>3,4</sup>, Elena R. Chernykh<sup>5</sup>, Alexandr A. Ostanin<sup>5</sup>, Olga Y. Leplina<sup>5</sup>, Victoria V. Dvornichenko<sup>6,7</sup>, Dmitriy M. Ponomarenko<sup>6,7</sup>, Galina S. Soldatova<sup>3,8</sup>, Nikolay A. Varaksin<sup>9</sup>, Tatiana G. Ryabicheva<sup>9</sup>, Peter N. Uchakin<sup>10</sup>, Stanislav N. Zagrebelniy<sup>3</sup>, Vladimir A. Rogachev<sup>1</sup>, Sergey S. Bogachev<sup>1\*</sup> and Mikhail A. Shurdov<sup>11</sup>

## Erratum

After publication of this work [1], we noted that we inadvertently failed to include the complete list of all co-authors. In this erratum we rectify these mistakes. The full list of authors and the updated Authors Contributions section are reported below. We apologize for any inconvenience this oversight may have caused.

### Corrected Authors' List:

Anastasia S. Proskurina, Tatiana S. Gvozdeva, Ekaterina A. Alyamkina, Evgenia V. Dolgova, Konstantin E. Orishchenko, Valeriy P. Nikolin, Nelly A. Popova, Sergey V. Sidorov, Elena R. Chernykh, Alexandr A. Ostanin, Olga Y. Leplina, Victoria V. Dvornichenko, Dmitriy M. Ponomarenko, Galina S. Soldatova, Nikolay A. Varaksin, Tatiana G. Ryabicheva, Peter N. Uchakin, Stanislav N. Zagrebelniy, Vladimir A. Rogachev, Sergey S. Bogachev, and Mikhail A. Shurdov.

### Authors' contributions

ASP performed the analysis, interpreted the data, and drafted the manuscript. TSG carried out clinical work with patients and drafted the manuscript. EAA carried out the molecular studies. EVD carried out the molecular studies. KEO performed the design of the study and provide the technical conditions to perform works. VPN performed the analysis and

interpreted the data. NAP participated in the design of the study. SVS carried out clinical work with patients and participated in study design. ERC participated in the design of the study. AAO performed the analysis and interpreted the data. OYL carried out experiments to estimate the adaptive immunity induction. WD helped in the data interpretation. DMP carried out clinical work with patients. GSS helped in the data interpretation. NAV, TGR and PNU carried out cytokine analysis. SNZ participated in the design of the study. VAR carried out production of DNA preparation. SSB conceived the study, participated in its design, and coordinated and drafted the manuscript. MAS participated in the study design and coordination. All authors read and approved the final manuscript.

### Author details

<sup>1</sup>Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk 630090, Russia. <sup>2</sup>Novosibirsk State Medical University, Novosibirsk 630091, Russia. <sup>3</sup>Novosibirsk State University, Novosibirsk 630090, Russia. <sup>4</sup>Oncology Department of Municipal Hospital No 1, Novosibirsk 630047, Russia. <sup>5</sup>Institute of Clinical Immunology, Siberian Branch of the Russian Academy of Medical Sciences, Novosibirsk 630099, Russia. <sup>6</sup>Irkutsk State Medical Academy of Postgraduate Education, Irkutsk 664049, Russia. <sup>7</sup>Regional Oncology Dispensary, Irkutsk 664035, Russia. <sup>8</sup>Clinic Department of the Central Clinical Hospital, Siberian Branch of the Russian Academy of Sciences, Novosibirsk 630090, Russia. <sup>9</sup>CJSC «Vector-best», Koltsovo, Novosibirsk region 630559, Russia. <sup>10</sup>Mercer University School of Medicine, Macon, Georgia 31207, USA. <sup>11</sup>LLC 1 Panagen, Gorno-Altai 649000, Russia.

Received: 11 February 2016 Accepted: 11 February 2016

Published online: 17 February 2016

### References

1. Proskurina AS, Gvozdeva TS, Alyamkina EA, Dolgova EV, Orishchenko KE, Nikolin VP, et al. Results of multicenter double-blind placebo-controlled phase II clinical trial of Panagen preparation to evaluate its leukostimulatory activity and formation of the adaptive immune response in patients with stage II-IV breast cancer. *BMC Cancer*. 2015;15:122. doi:10.1186/s12885-015-1142-z.

\* Correspondence: labmolbiol@mail.ru

†Equal contributors

<sup>1</sup>Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk 630090, Russia

Full list of author information is available at the end of the article

